Alnylam Pharmaceuticals | Beneficio Bruto En Ventas



Gross Profit On Sales Cambio Fecha
Acadia Pharmaceuticals USD 243.83M 19.91M 2025-06
Agios Pharmaceuticals USD 10.75M 3.11M 2025-06
Alnylam Pharmaceuticals USD 630.74M 107.59M 2025-06
Amgen USD 6.17B 624M 2025-06
Arrowhead Research 27.77M 514.94M 2025-06
BioMarin Pharmaceutical USD 670.47M 76.89M 2025-06
Incyte USD 1.14B 151.67M 2025-06
Ionis Pharmaceuticals USD 448M 317.85M 2025-06
Moderna USD 18M 1000K 2025-06
Neurocrine Biosciences USD 676.2M 112.8M 2025-06
Novartis USD 10.24B 313M 2024-12
PTC Therapeutics USD 163.39M 999.84M 2025-06
Regeneron Pharmaceuticals USD 3.15B 581M 2025-06
Sanofi EUR 5.36B 4.71B 2024-12
Sarepta Therapeutics USD 457.87M 149.43M 2025-06
Takeda JPY 722.01B 50.69B 2025-06
Tectonic Therapeutic 0 0 2025-03
Ultragenyx Pharmaceutical USD 143.49M 32.86M 2025-06
Vertex Pharmaceuticals USD 2.56B 150M 2025-06
Xencor 43.61M 10.88M 2025-06


Alnylam Pharmaceuticals Beneficio Bruto En Ventas - Los valores actuales, los datos históricos, las previsiones, estadísticas, gráficas y calendario económico - Aug 2025.